PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($2.13), $0.76 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $166 million versus the consensus estimate of $162.12 million.

GUIDANCE:

PTC Therapeutics sees Q3 2022 revenue of $700-750 million, versus the consensus of $722.95 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.